February 28, 2017 08:47 AM EST
R&D
Pharma

Cem­pra slash­es staff while shares tank (again) af­ter a new se­ries of set­backs for lead an­tibi­ot­ic

John Carroll

Editor & Founder

Cem­pra’s Q4 re­view to­day in­cludes a slate of new set­backs, rang­ing from a fail­ure for a Phase III non-in­fe­ri­or­i­ty tri­al of its an­tibi­ot­ic solithromycin in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times